Fujian Shengdi Pharmaceutical Co., Ltd. clinical trials

A subsidiary of Jiangsu HengRui Medicine Co., Ltd.

The registry lists 66 studies whose lead sponsor is Fujian Shengdi Pharmaceutical Co., Ltd.. 25 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 66. List all 66 → · All Jiangsu HengRui Medicine Co., Ltd. studies →

• A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With HypertriglyceridemiaRecruitingNCT07799688Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study of HRS-4729 Injection in Participants With Type 2 DiabetesNot yet recruitingNCT07843862Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of HRS-4139 in Healthy ParticipantsRecruitingNCT07802964Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets in Healthy Participants With a Single Dose and in Obese Participants With Multiple DosesNot yet recruitingNCT07841860Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid RetentionRecruitingNCT07318103Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal ImpairmentRecruitingNCT07807059Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular DiseaseRecruitingNCT07551492Phase 3

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated SteatohepatitisRecruitingNCT07660848Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Clinical Trial of HRS5580 for Injection Combined With Palonosetron Hydrochloride for the Prevention of Postoperative Nausea and VomitingRecruitingNCT07709897Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsRecruitingNCT07670884Phase 3

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis BRecruitingNCT07606950Phase 3

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes MellitusRecruitingNCT07599410Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Trial of Ribupatide Injection in Participants With Obesity and Knee OsteoarthritisNot yet recruitingNCT07709910Phase 3

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in ObesityNot yet recruitingNCT07690826Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy ParticipantsNot yet recruitingNCT06506175Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic FunctionRecruitingNCT07540754Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) TherapyRecruitingNCT06994650Phase 3

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal InsulinRecruitingNCT07060456Phase 3

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis BRecruitingNCT06425341Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 InjectionRecruitingNCT06934408Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and ObesityRecruitingNCT06974851Phase 3

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight SubjectsRecruitingNCT07150962Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep ApneaNot yet recruitingNCT06565871Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Trial of HRS-7450 in Chinese Healthy VolunteersNot yet recruitingNCT06087094Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis BRecruitingNCT05808374Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without DiabetesCompletedNCT05881837Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.CompletedNCT07233070Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With ObesityActive, not recruitingNCT07559136Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Single Ascending Dose of HRS-2162 in Healthy SubjectsCompletedNCT07195604Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive CandidiasisCompletedNCT06194201Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Mass Balance Study of [14C]HRS-9057 for Injection in Healthy ParticipantsActive, not recruitingNCT07681479Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute PancreatitisActive, not recruitingNCT07308392Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.CompletedNCT07117474Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate HypertensionActive, not recruitingNCT07297797Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 DiabetesCompletedNCT06649344Phase 3

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise AloneCompletedNCT06650007Phase 3

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With HyperlipidemiaActive, not recruitingNCT07100418Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• Efficacy and Safety of HRS9531 Injections in Overweight or Obese SubjectsCompletedNCT06054698Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy SubjectsCompletedNCT06246175Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy SubjectsCompletedNCT06762600Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy SubjectsCompletedNCT06732154Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• Efficacy and Safety of HRS9531 Tablet in Obese SubjectsCompletedNCT06841445Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular EventsActive, not recruitingNCT07185776Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With ObesityActive, not recruitingNCT07285902Phase 3

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection FractionActive, not recruitingNCT06391710Phase 2

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study of HRS-9057 in Patients With Heart Failure and Volume OverloadCompletedNCT06506994Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer AgentsCompletedNCT06554184Phase 3

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical TrialCompletedNCT06447415Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy SubjectsCompletedNCT06541457Phase 1

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.

• To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or ObeseCompletedNCT06396429Phase 3

  Sponsor listed in the registry: Fujian Shengdi Pharmaceutical Co., Ltd.